# MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD)

> **NCT02410239** · PHASE1 · WITHDRAWN · sponsor: **Masonic Cancer Center, University of Minnesota**

## Conditions studied

- Cerebral Adrenoleukodystrophy

## Interventions

- **BIOLOGICAL:** Mesenchymal Stem Cells

## Key facts

- **NCT ID:** NCT02410239
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-06
- **Primary completion:** 2017-07
- **Final completion:** 2022-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Research cancelled
- **Last updated:** 2017-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02410239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02410239, "MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02410239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*